ResMed Inc. (RMD) Stock Competitors & Peer Comparison
See (RMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMD | $201.10 | +3.19% | 29.2B | 18.68 | $10.77 | +1.19% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $92.18 | +1.59% | 160.5B | 17.69 | $5.21 | +2.65% |
| ISRG | $402.38 | +1.18% | 142.5B | 41.83 | $9.62 | N/A |
| SYK | $313.39 | -0.46% | 120.1B | 23.40 | $13.39 | +1.11% |
| MDT | $79.20 | +1.24% | 101.4B | 14.32 | $5.53 | +3.59% |
| BSX | $43.06 | +0.89% | 64B | 13.89 | $3.10 | N/A |
| EW | $91.99 | +1.69% | 53B | 34.07 | $2.70 | N/A |
| DXCM | $68.86 | +2.24% | 26.6B | 29.55 | $2.33 | N/A |
| ABMD | $381.02 | +0.00% | 17.2B | 65.36 | $5.83 | N/A |
Stock Comparison
RMD vs BSX-PA Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RMD is priced at $201.10, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RMD's ROE is +0.24%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RMD is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BSX-PA's competition here
RMD vs ABT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ABT has a market cap of 160.5B. Regarding current trading prices, RMD is priced at $201.10, while ABT trades at $92.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ABT's P/E ratio is 17.69. In terms of profitability, RMD's ROE is +0.24%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ABT's competition here
RMD vs ISRG Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, RMD is priced at $201.10, while ISRG trades at $402.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ISRG's P/E ratio is 41.83. In terms of profitability, RMD's ROE is +0.24%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RMD is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here
RMD vs SYK Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SYK has a market cap of 120.1B. Regarding current trading prices, RMD is priced at $201.10, while SYK trades at $313.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SYK's P/E ratio is 23.40. In terms of profitability, RMD's ROE is +0.24%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SYK's competition here
RMD vs MDT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, MDT has a market cap of 101.4B. Regarding current trading prices, RMD is priced at $201.10, while MDT trades at $79.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas MDT's P/E ratio is 14.32. In terms of profitability, RMD's ROE is +0.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MDT's competition here
RMD vs BSX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BSX has a market cap of 64B. Regarding current trading prices, RMD is priced at $201.10, while BSX trades at $43.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BSX's P/E ratio is 13.89. In terms of profitability, RMD's ROE is +0.24%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RMD is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BSX's competition here
RMD vs EW Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, EW has a market cap of 53B. Regarding current trading prices, RMD is priced at $201.10, while EW trades at $91.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas EW's P/E ratio is 34.07. In terms of profitability, RMD's ROE is +0.24%, compared to EW's ROE of +0.11%. Regarding short-term risk, RMD is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check EW's competition here
RMD vs DXCM Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, DXCM has a market cap of 26.6B. Regarding current trading prices, RMD is priced at $201.10, while DXCM trades at $68.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas DXCM's P/E ratio is 29.55. In terms of profitability, RMD's ROE is +0.24%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RMD is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check DXCM's competition here
RMD vs ABMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RMD is priced at $201.10, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RMD's ROE is +0.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ABMD's competition here
RMD vs ZBH Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ZBH has a market cap of 16.3B. Regarding current trading prices, RMD is priced at $201.10, while ZBH trades at $84.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ZBH's P/E ratio is 9.93. In terms of profitability, RMD's ROE is +0.24%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RMD is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ZBH's competition here
RMD vs ALGN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ALGN has a market cap of 13B. Regarding current trading prices, RMD is priced at $201.10, while ALGN trades at $181.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ALGN's P/E ratio is 16.54. In terms of profitability, RMD's ROE is +0.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ALGN's competition here
RMD vs SWAV Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RMD is priced at $201.10, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RMD's ROE is +0.24%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SWAV's competition here
RMD vs PEN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PEN has a market cap of 12.4B. Regarding current trading prices, RMD is priced at $201.10, while PEN trades at $316.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PEN's P/E ratio is 82.61. In terms of profitability, RMD's ROE is +0.24%, compared to PEN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PEN's competition here
RMD vs SNN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, RMD is priced at $201.10, while SNN trades at $28.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SNN's P/E ratio is 15.52. In terms of profitability, RMD's ROE is +0.24%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SNN's competition here
RMD vs PODD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PODD has a market cap of 11.1B. Regarding current trading prices, RMD is priced at $201.10, while PODD trades at $159.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PODD's P/E ratio is 29.70. In terms of profitability, RMD's ROE is +0.24%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RMD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PODD's competition here
RMD vs GMED Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, RMD is priced at $201.10, while GMED trades at $75.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas GMED's P/E ratio is 17.11. In terms of profitability, RMD's ROE is +0.24%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GMED's competition here
RMD vs MASI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RMD is priced at $201.10, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas MASI's P/E ratio is 44.43. In terms of profitability, RMD's ROE is +0.24%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MASI's competition here
RMD vs BRKR Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BRKR has a market cap of 9.2B. Regarding current trading prices, RMD is priced at $201.10, while BRKR trades at $60.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BRKR's P/E ratio is 33.32. In terms of profitability, RMD's ROE is +0.24%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RMD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BRKR's competition here
RMD vs GKOS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, GKOS has a market cap of 8.1B. Regarding current trading prices, RMD is priced at $201.10, while GKOS trades at $137.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas GKOS's P/E ratio is -159.81. In terms of profitability, RMD's ROE is +0.24%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GKOS's competition here
RMD vs BIO-B Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BIO-B has a market cap of 8B. Regarding current trading prices, RMD is priced at $201.10, while BIO-B trades at $298.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BIO-B's P/E ratio is 88.66. In terms of profitability, RMD's ROE is +0.24%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BIO-B's competition here
RMD vs BIO Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BIO has a market cap of 8B. Regarding current trading prices, RMD is priced at $201.10, while BIO trades at $297.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BIO's P/E ratio is 32.07. In terms of profitability, RMD's ROE is +0.24%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RMD is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BIO's competition here
RMD vs NARI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RMD is priced at $201.10, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NARI's P/E ratio is -59.24. In terms of profitability, RMD's ROE is +0.24%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NARI's competition here
RMD vs LIVN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, RMD is priced at $201.10, while LIVN trades at $82.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas LIVN's P/E ratio is 20.62. In terms of profitability, RMD's ROE is +0.24%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check LIVN's competition here
RMD vs IRTC Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, RMD is priced at $201.10, while IRTC trades at $124.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas IRTC's P/E ratio is -222.37. In terms of profitability, RMD's ROE is +0.24%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRTC's competition here
RMD vs AXNX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RMD is priced at $201.10, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RMD's ROE is +0.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AXNX's competition here
RMD vs ITGR Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, RMD is priced at $201.10, while ITGR trades at $94.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ITGR's P/E ratio is 15.02. In terms of profitability, RMD's ROE is +0.24%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RMD is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ITGR's competition here
RMD vs ESTA Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ESTA has a market cap of 2.6B. Regarding current trading prices, RMD is priced at $201.10, while ESTA trades at $89.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ESTA's P/E ratio is -61.97. In terms of profitability, RMD's ROE is +0.24%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ESTA's competition here
RMD vs TMDX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, RMD is priced at $201.10, while TMDX trades at $67.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas TMDX's P/E ratio is 27.69. In terms of profitability, RMD's ROE is +0.24%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMDX's competition here
RMD vs AXGN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, RMD is priced at $201.10, while AXGN trades at $44.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AXGN's P/E ratio is 115.84. In terms of profitability, RMD's ROE is +0.24%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AXGN's competition here
RMD vs NUVA Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $201.10, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RMD's ROE is +0.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NUVA's competition here
RMD vs UFPT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, UFPT has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $201.10, while UFPT trades at $268.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas UFPT's P/E ratio is 27.39. In terms of profitability, RMD's ROE is +0.24%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check UFPT's competition here
RMD vs BFLY Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $201.10, while BFLY trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BFLY's P/E ratio is -33.08. In terms of profitability, RMD's ROE is +0.24%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BFLY's competition here
RMD vs NVCR Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, RMD is priced at $201.10, while NVCR trades at $15.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NVCR's P/E ratio is -10.31. In terms of profitability, RMD's ROE is +0.24%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NVCR's competition here
RMD vs AHCO Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, RMD is priced at $201.10, while AHCO trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AHCO's P/E ratio is 24.09. In terms of profitability, RMD's ROE is +0.24%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RMD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AHCO's competition here
RMD vs IART Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, RMD is priced at $201.10, while IART trades at $17.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas IART's P/E ratio is 7.58. In terms of profitability, RMD's ROE is +0.24%, compared to IART's ROE of -0.48%. Regarding short-term risk, RMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IART's competition here
RMD vs ATEC Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, RMD is priced at $201.10, while ATEC trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ATEC's P/E ratio is -80.55. In terms of profitability, RMD's ROE is +0.24%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ATEC's competition here
RMD vs PRCT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $201.10, while PRCT trades at $23.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PRCT's P/E ratio is -12.90. In terms of profitability, RMD's ROE is +0.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PRCT's competition here
RMD vs INSP Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $201.10, while INSP trades at $45.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas INSP's P/E ratio is 17.62. In terms of profitability, RMD's ROE is +0.24%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INSP's competition here
RMD vs HSKA Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $201.10, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RMD's ROE is +0.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check HSKA's competition here
RMD vs IRMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $201.10, while IRMD trades at $98.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas IRMD's P/E ratio is 49.27. In terms of profitability, RMD's ROE is +0.24%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RMD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRMD's competition here
RMD vs ENOV Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $201.10, while ENOV trades at $20.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ENOV's P/E ratio is 5.93. In terms of profitability, RMD's ROE is +0.24%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RMD is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ENOV's competition here
RMD vs AVNS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $201.10, while AVNS trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AVNS's P/E ratio is 27.34. In terms of profitability, RMD's ROE is +0.24%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RMD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AVNS's competition here
RMD vs AORT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $201.10, while AORT trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AORT's P/E ratio is 36.24. In terms of profitability, RMD's ROE is +0.24%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AORT's competition here
RMD vs SILK Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $201.10, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SILK's P/E ratio is -18.96. In terms of profitability, RMD's ROE is +0.24%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SILK's competition here
RMD vs LMRI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $201.10, while LMRI trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas LMRI's P/E ratio is -22.55. In terms of profitability, RMD's ROE is +0.24%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, RMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LMRI's competition here
RMD vs FNA Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $201.10, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas FNA's P/E ratio is -19.83. In terms of profitability, RMD's ROE is +0.24%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check FNA's competition here
RMD vs TNDM Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $201.10, while TNDM trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas TNDM's P/E ratio is -14.32. In terms of profitability, RMD's ROE is +0.24%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TNDM's competition here
RMD vs CNMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CNMD has a market cap of 986.4M. Regarding current trading prices, RMD is priced at $201.10, while CNMD trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CNMD's P/E ratio is 7.20. In terms of profitability, RMD's ROE is +0.24%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CNMD's competition here
RMD vs CSII Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RMD is priced at $201.10, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CSII's P/E ratio is -20.83. In terms of profitability, RMD's ROE is +0.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check CSII's competition here
RMD vs INMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, INMD has a market cap of 843.8M. Regarding current trading prices, RMD is priced at $201.10, while INMD trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas INMD's P/E ratio is 9.41. In terms of profitability, RMD's ROE is +0.24%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RMD is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check INMD's competition here
RMD vs SSII Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SSII has a market cap of 798.5M. Regarding current trading prices, RMD is priced at $201.10, while SSII trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SSII's P/E ratio is -77.82. In terms of profitability, RMD's ROE is +0.24%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RMD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SSII's competition here
RMD vs CBLL Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CBLL has a market cap of 758.9M. Regarding current trading prices, RMD is priced at $201.10, while CBLL trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CBLL's P/E ratio is -12.27. In terms of profitability, RMD's ROE is +0.24%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CBLL's competition here
RMD vs SIBN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SIBN has a market cap of 745.1M. Regarding current trading prices, RMD is priced at $201.10, while SIBN trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SIBN's P/E ratio is -43.08. In terms of profitability, RMD's ROE is +0.24%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RMD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SIBN's competition here
RMD vs CRY Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RMD is priced at $201.10, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CRY's P/E ratio is 425.71. In terms of profitability, RMD's ROE is +0.24%, compared to CRY's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CRY's competition here
RMD vs TCMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, TCMD has a market cap of 691.4M. Regarding current trading prices, RMD is priced at $201.10, while TCMD trades at $30.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas TCMD's P/E ratio is 34.83. In terms of profitability, RMD's ROE is +0.24%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TCMD's competition here
RMD vs BVS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BVS has a market cap of 667.3M. Regarding current trading prices, RMD is priced at $201.10, while BVS trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BVS's P/E ratio is 13.13. In terms of profitability, RMD's ROE is +0.24%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BVS's competition here
RMD vs SRDX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RMD is priced at $201.10, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RMD's ROE is +0.24%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, RMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SRDX's competition here
RMD vs CERS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CERS has a market cap of 601.1M. Regarding current trading prices, RMD is priced at $201.10, while CERS trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CERS's P/E ratio is -59.88. In terms of profitability, RMD's ROE is +0.24%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CERS's competition here
RMD vs BWAY Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BWAY has a market cap of 599.7M. Regarding current trading prices, RMD is priced at $201.10, while BWAY trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BWAY's P/E ratio is 38.84. In terms of profitability, RMD's ROE is +0.24%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BWAY's competition here
RMD vs CTKB Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CTKB has a market cap of 591.5M. Regarding current trading prices, RMD is priced at $201.10, while CTKB trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CTKB's P/E ratio is -35.23. In terms of profitability, RMD's ROE is +0.24%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CTKB's competition here
RMD vs APEN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RMD is priced at $201.10, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas APEN's P/E ratio is -9.43. In terms of profitability, RMD's ROE is +0.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check APEN's competition here
RMD vs CLPT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CLPT has a market cap of 561.4M. Regarding current trading prices, RMD is priced at $201.10, while CLPT trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CLPT's P/E ratio is -18.53. In terms of profitability, RMD's ROE is +0.24%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CLPT's competition here
RMD vs PACB Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PACB has a market cap of 540.4M. Regarding current trading prices, RMD is priced at $201.10, while PACB trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PACB's P/E ratio is -3.55. In terms of profitability, RMD's ROE is +0.24%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PACB's competition here
RMD vs NPCE Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NPCE has a market cap of 537.7M. Regarding current trading prices, RMD is priced at $201.10, while NPCE trades at $15.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NPCE's P/E ratio is -27.19. In terms of profitability, RMD's ROE is +0.24%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NPCE's competition here
RMD vs ZIMV Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RMD is priced at $201.10, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RMD's ROE is +0.24%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ZIMV's competition here
RMD vs KIDS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, KIDS has a market cap of 495.7M. Regarding current trading prices, RMD is priced at $201.10, while KIDS trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas KIDS's P/E ratio is -18.74. In terms of profitability, RMD's ROE is +0.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check KIDS's competition here
RMD vs VREX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, VREX has a market cap of 449.6M. Regarding current trading prices, RMD is priced at $201.10, while VREX trades at $10.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas VREX's P/E ratio is 11.24. In terms of profitability, RMD's ROE is +0.24%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RMD is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check VREX's competition here
RMD vs DCTH Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, DCTH has a market cap of 445.7M. Regarding current trading prices, RMD is priced at $201.10, while DCTH trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas DCTH's P/E ratio is 1291.00. In terms of profitability, RMD's ROE is +0.24%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RMD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DCTH's competition here
RMD vs OFIX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, OFIX has a market cap of 377.9M. Regarding current trading prices, RMD is priced at $201.10, while OFIX trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas OFIX's P/E ratio is -38.09. In terms of profitability, RMD's ROE is +0.24%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check OFIX's competition here
RMD vs AVR Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, AVR has a market cap of 365.7M. Regarding current trading prices, RMD is priced at $201.10, while AVR trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas AVR's P/E ratio is -4.46. In terms of profitability, RMD's ROE is +0.24%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AVR's competition here
RMD vs ELMD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ELMD has a market cap of 363.6M. Regarding current trading prices, RMD is priced at $201.10, while ELMD trades at $44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ELMD's P/E ratio is 37.53. In terms of profitability, RMD's ROE is +0.24%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ELMD's competition here
RMD vs SMLR Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RMD is priced at $201.10, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RMD's ROE is +0.24%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SMLR's competition here
RMD vs SGHT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SGHT has a market cap of 296M. Regarding current trading prices, RMD is priced at $201.10, while SGHT trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SGHT's P/E ratio is -8.63. In terms of profitability, RMD's ROE is +0.24%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SGHT's competition here
RMD vs TMCI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, TMCI has a market cap of 274.4M. Regarding current trading prices, RMD is priced at $201.10, while TMCI trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas TMCI's P/E ratio is -4.50. In terms of profitability, RMD's ROE is +0.24%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMCI's competition here
RMD vs PMI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PMI has a market cap of 271.8M. Regarding current trading prices, RMD is priced at $201.10, while PMI trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PMI's P/E ratio is -0.15. In terms of profitability, RMD's ROE is +0.24%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PMI's competition here
RMD vs CATX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CATX has a market cap of 266.5M. Regarding current trading prices, RMD is priced at $201.10, while CATX trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CATX's P/E ratio is -2.45. In terms of profitability, RMD's ROE is +0.24%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CATX's competition here
RMD vs MGRM Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RMD is priced at $201.10, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas MGRM's P/E ratio is -12.00. In terms of profitability, RMD's ROE is +0.24%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, RMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MGRM's competition here
RMD vs NVRO Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RMD is priced at $201.10, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RMD's ROE is +0.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NVRO's competition here
RMD vs SENS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, SENS has a market cap of 224M. Regarding current trading prices, RMD is priced at $201.10, while SENS trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas SENS's P/E ratio is -2.68. In terms of profitability, RMD's ROE is +0.24%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SENS's competition here
RMD vs RXST Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, RXST has a market cap of 214M. Regarding current trading prices, RMD is priced at $201.10, while RXST trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas RXST's P/E ratio is -7.18. In terms of profitability, RMD's ROE is +0.24%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RXST's competition here
RMD vs EYES Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RMD is priced at $201.10, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas EYES's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to EYES's ROE of -2.64%. Regarding short-term risk, RMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EYES's competition here
RMD vs QTRX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, QTRX has a market cap of 204.4M. Regarding current trading prices, RMD is priced at $201.10, while QTRX trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas QTRX's P/E ratio is -2.71. In terms of profitability, RMD's ROE is +0.24%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QTRX's competition here
RMD vs PROF Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, PROF has a market cap of 204.3M. Regarding current trading prices, RMD is priced at $201.10, while PROF trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas PROF's P/E ratio is -5.44. In terms of profitability, RMD's ROE is +0.24%, compared to PROF's ROE of -0.70%. Regarding short-term risk, RMD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PROF's competition here
RMD vs ANIK Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ANIK has a market cap of 202M. Regarding current trading prices, RMD is priced at $201.10, while ANIK trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ANIK's P/E ratio is 30.98. In terms of profitability, RMD's ROE is +0.24%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ANIK's competition here
RMD vs FOCL Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, FOCL has a market cap of 194.9M. Regarding current trading prices, RMD is priced at $201.10, while FOCL trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas FOCL's P/E ratio is -10.51. In terms of profitability, RMD's ROE is +0.24%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, RMD is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check FOCL's competition here
RMD vs BSGM Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RMD is priced at $201.10, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RMD's ROE is +0.24%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSGM's competition here
RMD vs INGN Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, INGN has a market cap of 180M. Regarding current trading prices, RMD is priced at $201.10, while INGN trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas INGN's P/E ratio is -7.31. In terms of profitability, RMD's ROE is +0.24%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INGN's competition here
RMD vs MDGS Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RMD is priced at $201.10, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RMD's ROE is +0.24%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MDGS's competition here
RMD vs TLSI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, TLSI has a market cap of 169.1M. Regarding current trading prices, RMD is priced at $201.10, while TLSI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas TLSI's P/E ratio is -2.65. In terms of profitability, RMD's ROE is +0.24%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, RMD is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TLSI's competition here
RMD vs QIPT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RMD is priced at $201.10, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RMD's ROE is +0.24%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check QIPT's competition here
RMD vs CVRX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, CVRX has a market cap of 145.9M. Regarding current trading prices, RMD is priced at $201.10, while CVRX trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas CVRX's P/E ratio is -2.72. In terms of profitability, RMD's ROE is +0.24%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CVRX's competition here
RMD vs RCEL Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, RCEL has a market cap of 116M. Regarding current trading prices, RMD is priced at $201.10, while RCEL trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas RCEL's P/E ratio is -2.97. In terms of profitability, RMD's ROE is +0.24%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, RMD is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RCEL's competition here
RMD vs OWLT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, OWLT has a market cap of 111.1M. Regarding current trading prices, RMD is priced at $201.10, while OWLT trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas OWLT's P/E ratio is -43.86. In terms of profitability, RMD's ROE is +0.24%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, RMD is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check OWLT's competition here
RMD vs QTI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, QTI has a market cap of 108.8M. Regarding current trading prices, RMD is priced at $201.10, while QTI trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas QTI's P/E ratio is -5.90. In terms of profitability, RMD's ROE is +0.24%, compared to QTI's ROE of -63.31%. Regarding short-term risk, RMD is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QTI's competition here
RMD vs LUCD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, LUCD has a market cap of 107.4M. Regarding current trading prices, RMD is priced at $201.10, while LUCD trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas LUCD's P/E ratio is -2.84. In terms of profitability, RMD's ROE is +0.24%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, RMD is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LUCD's competition here
RMD vs ICAD Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RMD is priced at $201.10, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RMD's ROE is +0.24%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, RMD is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ICAD's competition here
RMD vs HSDT Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, RMD is priced at $201.10, while HSDT trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas HSDT's P/E ratio is -0.02. In terms of profitability, RMD's ROE is +0.24%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, RMD is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check HSDT's competition here
RMD vs HJLI Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, RMD is priced at $201.10, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas HJLI's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, RMD is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check HJLI's competition here
RMD vs NNOX Comparison July 2026
RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 29.2B. In comparison, NNOX has a market cap of 96M. Regarding current trading prices, RMD is priced at $201.10, while NNOX trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 18.68, whereas NNOX's P/E ratio is -0.87. In terms of profitability, RMD's ROE is +0.24%, compared to NNOX's ROE of -0.52%. Regarding short-term risk, RMD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NNOX's competition here